BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 56 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,639,300 | -43.2% | 1,690,000 | -42.5% | 0.12% | -38.1% |
| Q2 2023 | $2,887,868 | -4.3% | 2,940,000 | 0.0% | 0.20% | -14.0% |
| Q1 2023 | $3,016,378 | -3.3% | 2,940,000 | 0.0% | 0.23% | -16.1% |
| Q4 2022 | $3,120,222 | +7.1% | 2,940,000 | 0.0% | 0.27% | +1.1% |
| Q3 2022 | $2,913,000 | +20.6% | 2,940,000 | +20.5% | 0.27% | +18.4% |
| Q2 2022 | $2,416,000 | +449.1% | 2,440,000 | +454.5% | 0.23% | +635.5% |
| Q1 2022 | $440,000 | -95.2% | 440,000 | -94.9% | 0.03% | -94.6% |
| Q4 2021 | $9,097,000 | +61.6% | 8,700,000 | +58.2% | 0.58% | +40.1% |
| Q3 2021 | $5,628,000 | +61.1% | 5,500,000 | +65.2% | 0.41% | +8.7% |
| Q3 2020 | $3,494,000 | -14.1% | 3,330,000 | 0.0% | 0.38% | -54.2% |
| Q2 2020 | $4,069,000 | +22.3% | 3,330,000 | +4.9% | 0.83% | +27.5% |
| Q1 2020 | $3,327,000 | – | 3,175,000 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wellesley Asset Management | 53,670 | $57,726,000 | 3.34% |
| SHENKMAN CAPITAL MANAGEMENT INC | 26,959,000 | $29,149,000 | 3.04% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 84,134,000 | $90,539,000 | 1.93% |
| Cheyne Capital Management (UK) LLP | 3,220,000 | $3,452,000 | 1.75% |
| PFM Health Sciences, LP | 40,300,000 | $43,210,000 | 1.52% |
| Sonora Investment Management, LLC | 6,370,000 | $6,807,000 | 0.56% |
| MACKAY SHIELDS LLC | 66,018,000 | $70,980,000 | 0.49% |
| ZAZOVE ASSOCIATES LLC | 1,500,000 | $1,608,000 | 0.20% |
| IRON Financial LLC | 275,000 | $295,000 | 0.15% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,000,000 | $3,216,000 | 0.08% |